Literature DB >> 24381159

Unraveling the challenges of pertussis.

Kathryn M Edwards1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24381159      PMCID： PMC3896212          DOI： 10.1073/pnas.1321360111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  18 in total

1.  Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.

Authors:  M Giuliano; P Mastrantonio; A Giammanco; A Piscitelli; S Salmaso; S G Wassilak
Journal:  J Pediatr       Date:  1998-06       Impact factor: 4.406

2.  Comparison of 13 acellular pertussis vaccines: overview and serologic response.

Authors:  K M Edwards; B D Meade; M D Decker; G F Reed; M B Rennels; M C Steinhoff; E L Anderson; J A Englund; M E Pichichero; M A Deloria
Journal:  Pediatrics       Date:  1995-09       Impact factor: 7.124

3.  Comparison of 13 acellular pertussis vaccines: adverse reactions.

Authors:  M D Decker; K M Edwards; M C Steinhoff; M B Rennels; M E Pichichero; J A Englund; E L Anderson; M A Deloria; G F Reed
Journal:  Pediatrics       Date:  1995-09       Impact factor: 7.124

4.  Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.

Authors:  S Salmaso; P Mastrantonio; A E Tozzi; P Stefanelli; A Anemona; M L Ciofi degli Atti; A Giammanco
Journal:  Pediatrics       Date:  2001-11       Impact factor: 7.124

5.  Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines.

Authors:  C M Ausiello; F Urbani; A la Sala; R Lande; A Cassone
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

6.  Pertussis is a frequent cause of prolonged cough illness in adults and adolescents.

Authors:  L D Senzilet; S A Halperin; J S Spika; M Alagaratnam; A Morris; B Smith
Journal:  Clin Infect Dis       Date:  2001-05-21       Impact factor: 9.079

7.  Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.

Authors:  Lennart Gustafsson; Luc Hessel; Jann Storsaeter; Patrick Olin
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

8.  Nonhuman primate model of pertussis.

Authors:  Jason M Warfel; Joel Beren; Vanessa K Kelly; Gloria Lee; Tod J Merkel
Journal:  Infect Immun       Date:  2012-01-17       Impact factor: 3.441

9.  A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.

Authors:  D Greco; S Salmaso; P Mastrantonio; M Giuliano; A E Tozzi; A Anemona; M L Ciofi degli Atti; A Giammanco; P Panei; W C Blackwelder; D L Klein; S G Wassilak
Journal:  N Engl J Med       Date:  1996-02-08       Impact factor: 91.245

10.  A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.

Authors:  L Gustafsson; H O Hallander; P Olin; E Reizenstein; J Storsaeter
Journal:  N Engl J Med       Date:  1996-02-08       Impact factor: 91.245
View more
  12 in total

1.  Dynamics of Pertussis Transmission in the United States.

Authors:  F M G Magpantay; P Rohani
Journal:  Am J Epidemiol       Date:  2015-05-27       Impact factor: 4.897

2.  Immune responses to pertussis antigens in infants and toddlers after immunization with multicomponent acellular pertussis vaccine.

Authors:  Olajumoke O Fadugba; Li Wang; Qingxia Chen; Natasha B Halasa
Journal:  Clin Vaccine Immunol       Date:  2014-09-24

3.  Epidemiological and Economic Effects of Priming With the Whole-Cell Bordetella pertussis Vaccine.

Authors:  Haedi DeAngelis; Samuel V Scarpino; Meagan C Fitzpatrick; Alison P Galvani; Benjamin M Althouse
Journal:  JAMA Pediatr       Date:  2016-05-01       Impact factor: 16.193

4.  Fine Epitope Mapping of Two Antibodies Neutralizing the Bordetella Adenylate Cyclase Toxin.

Authors:  Xianzhe Wang; James A Stapleton; Justin R Klesmith; Erik L Hewlett; Timothy A Whitehead; Jennifer A Maynard
Journal:  Biochemistry       Date:  2017-02-23       Impact factor: 3.162

5.  Using age-stratified incidence data to examine the transmission consequences of pertussis vaccination.

Authors:  J C Blackwood; D A T Cummings; S Iamsirithaworn; P Rohani
Journal:  Epidemics       Date:  2016-03-19       Impact factor: 4.396

Review 6.  Pertussis: Microbiology, Disease, Treatment, and Prevention.

Authors:  Paul E Kilgore; Abdulbaset M Salim; Marcus J Zervos; Heinz-Josef Schmitt
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 7.  Protecting Newborns Against Pertussis: Treatment and Prevention Strategies.

Authors:  Abdulbaset M Salim; Yan Liang; Paul E Kilgore
Journal:  Paediatr Drugs       Date:  2015-12       Impact factor: 3.022

8.  Development and validation of a robust multiplex serological assay to quantify antibodies specific to pertussis antigens.

Authors:  Gowrisankar Rajam; George Carlone; Ellie Kim; Jin Choi; Simon Paulos; SoHee Park; Amilia Jeyachandran; Yamini Gorantla; Emily Wong; Amit Sabnis; Peter Browning; Rita Desai; Conrad P Quinn; Jarad Schiffer
Journal:  Biologicals       Date:  2018-11-18       Impact factor: 1.856

9.  Asymptomatic transmission and the resurgence of Bordetella pertussis.

Authors:  Benjamin M Althouse; Samuel V Scarpino
Journal:  BMC Med       Date:  2015-06-24       Impact factor: 8.775

10.  Cost-Effectiveness of Pertussis Vaccination Schedule in Israel.

Authors:  Dean Langsam; Dor Kahana; Erez Shmueli; Dan Yamin
Journal:  Vaccines (Basel)       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.